Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer

(marketscreener.com) New Biomarkers of Response and Resistance that Suggest Pepinemab Could Offer New Combination Treatment OptionsROCHESTER, N.Y., Nov. 10, 2022 -- Vaccinex, Inc. , a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative diseases through the inhibition of semaphorin 4D , and its...https://www.marketscreener.com/quote/stock/VACCINEX-INC-45256990/news/Vaccinex-and-its-Collaborators-Present-Two-Abstracts-Related-to-Pepinemab-Combination-Immunotherapy-42271402/?utm_medium=RSS&utm_content=20221110